ASCO 2017 | Biosimilars are alternatives for original antibodies

Gunter von Minckwitz, MD, PhD from the German Breast Group Research Institute, Neu-Isenburg, Germany discusses biosimilars at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL. Dr Minckwitz emphasizes the importance of biosimilars in cancer treatment and how they will provide alternatives to the original and reduce costs. It is also mentioned that biosimilars undergo extensive testing before they are released into the market, therefore their effect should be identical to the original antibody.